BioReliance, a provider of contract services to the pharmaceutical and biopharmaceutical industries, has introduced its new protein array platform that is said to offer greater sensitivity, reduced testing time and reliable results.


According to the company, the platform, brand-named ReliArray, can simultaneously screen for four non-human pathogens in animal serum. ReliArray offers specific screening targeted toward the most common non-human primate pathogens, including B-virus, simian retroviruses, simian immunodeficiency virus and simian T-cell lymphotropic or leukemia virus.

Each protein array slide contains a collection of microscopic protein antigens arrayed onto the slide surface, enabling the simultaneous screening for antibodies against multiple pathogens. Array data are collected and quantified with BioReliance's proprietary array analysis software.

John Kolman, senior director of R&D at BioReliance, said: "It is essential to researchers that they can depend on the results of serological screenings. These tests ensure that their research animals are healthy and will keep their research results uncompromised.

"Until ReliArray was developed, serological testing methodologies have had limited sensitivity and results could vary from sample to sample. Not only does ReliArray allow faster turnaround, it also provides greater specificity, sensitivity and scalability."